Loading...
XJPX9987
Market cap1.85bUSD
Dec 26, Last price  
4,682.00JPY
1D
0.15%
1Q
-7.91%
Jan 2017
22.57%
Name

Suzuken Co Ltd

Chart & Performance

D1W1MN
XJPX:9987 chart
P/E
10.04
P/S
0.12
EPS
466.15
Div Yield, %
2.16%
Shrs. gr., 5y
-2.83%
Rev. gr., 5y
2.28%
Revenues
2.39t
+3.10%
1,330,982,000,0001,388,694,000,0001,454,842,000,0001,586,583,000,0001,641,386,000,0001,735,481,000,0001,751,961,000,0001,859,934,000,0001,894,611,000,0001,988,137,000,0001,969,683,000,0002,228,204,000,0002,127,076,000,0002,124,016,000,0002,132,345,000,0002,213,532,000,0002,128,478,000,0002,232,774,000,0002,314,828,000,0002,386,493,000,000
Net income
29.02b
+42.62%
12,576,000,00017,183,000,00017,702,000,00021,327,000,0007,072,000,00013,969,000,0009,627,000,0008,050,000,00014,350,000,00021,447,000,00018,920,000,00028,960,000,00021,308,000,00018,820,000,00030,204,000,00028,213,000,0007,895,000,00014,393,000,00020,345,000,00029,016,000,000
CFO
87.22b
+134.01%
18,094,000,00019,636,000,00068,117,000,000-16,118,000,000-4,583,000,00031,913,000,00028,336,000,00065,542,000,00054,006,000,000-41,054,000,00047,209,000,00020,457,000,00027,013,000,00098,066,000,00041,751,000,000-25,817,000,00015,602,000,0009,520,000,00037,270,000,00087,216,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 07, 2025

Profile

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
URL
https://www.suzuken.co.jp/
IPO date
Aug 01, 1994
Employees
13,429
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,386,493,000
3.10%
2,314,828,000
3.67%
2,232,774,000
4.90%
Cost of revenue
2,354,896,000
2,285,174,000
2,076,372,000
Unusual Expense (Income)
NOPBT
31,597,000
29,654,000
156,402,000
NOPBT Margin
1.32%
1.28%
7.00%
Operating Taxes
13,793,000
10,275,000
8,012,000
Tax Rate
43.65%
34.65%
5.12%
NOPAT
17,804,000
19,379,000
148,390,000
Net income
29,016,000
42.62%
20,345,000
41.35%
14,393,000
82.31%
Dividends
(6,287,000)
(6,331,000)
(6,377,000)
Dividend yield
1.67%
2.20%
1.99%
Proceeds from repurchase of equity
(25,001,000)
(19,113,000)
(4,409,000)
BB yield
6.65%
6.64%
1.38%
Debt
Debt current
287,000
362,000
Long-term debt
3,120,000
1,516,000
1,516,000
Deferred revenue
Other long-term liabilities
5,070,000
6,384,000
6,966,000
Net debt
(346,231,000)
(319,923,000)
(324,368,000)
Cash flow
Cash from operating activities
87,216,000
37,270,000
9,520,000
CAPEX
(15,640,000)
(17,742,000)
(14,292,000)
Cash from investing activities
10,350,000
(46,361,000)
1,439,000
Cash from financing activities
(31,716,000)
(26,219,000)
(11,599,000)
FCF
13,936,000
13,668,000
145,149,000
Balance
Cash
242,112,000
192,703,000
201,463,000
Long term investments
107,239,000
129,023,000
124,783,000
Excess cash
230,026,350
205,984,600
214,607,300
Stockholders' equity
384,495,000
759,764,000
825,903,000
Invested Capital
193,030,650
205,239,400
204,426,700
ROIC
8.94%
9.46%
75.47%
ROCE
7.11%
6.93%
35.72%
EV
Common stock shares outstanding
81,079
86,039
88,203
Price
4,639.00
38.68%
3,345.00
-7.85%
3,630.00
-16.07%
Market cap
376,125,481
30.69%
287,800,455
-10.11%
320,176,890
-17.00%
EV
30,015,481
348,514,455
381,859,890
EBITDA
40,160,000
38,293,000
165,962,000
EV/EBITDA
0.75
9.10
2.30
Interest
43,000
42,000
51,000
Interest/NOPBT
0.14%
0.14%
0.03%